Hospital Italiano de Buenos Aires
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label Study of XEN1101 in Epilepsy | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Tonic-Clonic Seizures, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Enrolling by invitation | Phase 3 | 2026-10-08 | NCT05718817 | |
| A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-10-01 | NCT07589634 | |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06632444 | |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-30 | NCT07361497 | |
| A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Abnormalities, Urogenital Diseases, adrenal gland disorder, adrenogenital syndrome, classic congenital adrenal hyperplasia, congenital adrenal hyperplasia, disorder of sexual differentiation, endocrine system disorder, gonadal disorder, hereditary disease, inborn errors of metabolism, metabolic disease, steroid inherited metabolic disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT07159841 | |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Primary Membranous Nephropathy | Recruiting | Phase 3 | 2026-09-29 | NCT06962800 | |
| A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 3 | 2026-09-25 | NCT06679140 | |
| Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT05327114 | |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05083169 | |
| A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Not stated | 2026-09-25 | NCT05049798 | |
| A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 4 | 2026-09-25 | NCT04929210 | |
| A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT04658862 | |
| A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, chronic renal failure syndrome, kidney disorder, kidney failure, proteinuria, urinary system disorder | Recruiting | Phase 3 | 2026-09-24 | NCT05457283 | |
| A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Advanced Non-small Cell Lung Cancer, HER2 Mutation | Recruiting | Phase 3 | 2026-09-23 | NCT06452277 | |
| A Gaucher Disease Gene Therapy Trial With FLT201 | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher Disease, Type 1, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis | Recruiting | Phase 3 | 2026-09-03 | NCT07223944 | |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Alzheimer disease, Amyloid Neuropathies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, amyloidosis, brain disorder, cardiomyopathy, cardiovascular disorder, central nervous system disorder, cognitive disorder, dementia, familial amyloid neuropathy, heart disorder, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, proteostasis deficiencies, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-08-04 | NCT06563895 | |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-07-16 | NCT04717414 | |
| A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | Left Ventricular Systolic Dysfunction, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-06-29 | NCT07192952 | |
| Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nodal marginal zone B-cell lymphoma | Recruiting | Not stated | 2026-06-22 | NCT05700149 | |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Left Ventricular Systolic Dysfunction, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-06-15 | NCT07188805 | |
| An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Enrolling by invitation | Phase 3 | 2026-04-17 | NCT05667493 | |
| A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Active, not recruiting | Phase 3 | 2025-12-04 | NCT05071300 | |
| A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease | Fabry Disesase | Recruiting | Phase 1 / Phase 2 | 2025-11-04 | NCT06858397 | |
| Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System | cardiovascular disorder, heart disorder | Recruiting | Not applicable | 2025-06-29 | NCT04861805 | |
| Munich Transcatheter Mitral Valve Safety and Effectiveness | cardiovascular disorder, heart disorder, heart failure, heart valve disorder, mitral valve disorder, mitral valve insufficiency | Not yet recruiting | Not applicable | 2023-07-11 | NCT05871983 |